Lung cancer is the leading cause of cancer deaths not only in Hungary but also in
the world. Within this, women's lung cancer morbidity and mortality have increased
significantly in recent years. For many years, we only had a chemotherapy option to
treat lung cancer. The year 2005 was a major breakthrough in the treatment of non-small
cell lung cancer with the advent of a new treatment strategy, targeted treatments,
EGFR-TKI treatments. Since then, we have several years of experience with first-,
second-, and even third-generation TKI treatments in lung adenocarcinoma. The second
major step in targeted therapy for lung cancer was to learn about ALK mutant lung
cancer and the emergence of ALK inhibitor therapies on the therapeutic palette with
the advent of first, second and third generation formulations. In recent years, the
range of options for targeted therapeutic targets has expanded to include personalized
therapeutic options. By recognizing and targeting the ROS1, BRAF, MET, RET, NTRK,
HER2 mutations, we can tailor the most optimal treatment to more and more patients.
